About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 145 nationalities work at Novartis around the world.
For more information, please visit www.novartis.com.
Sanofi Genzyme, the specialty care global business unit of Sanofi, focuses on developing therapies in oncology, rare diseases, rare blood disorders, multiple sclerosis, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. In oncology, we are building on a rich legacy with a strong pipeline and a continued commitment to contribute meaningful solutions for patients with cancer. Through rigorous drug discovery and development rooted in cutting-edge science and innovative technologies, we are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.
Learn more at www.sanofigenzyme.com.
About Pierre Fabre
Pierre Fabre is a French pharmaceutical and dermo-cosmetic laboratory, with 35-year experience in innovation, development, manufacturing and commercialization in oncology. The Group recently reaffirmed that oncology is one of its priorities in R&D and from a business perspective, focusing on targeted therapies, biotherapies and immuno-oncology. Its scope of therapeutic activity covers medical niches for which it does not exist treatment, such as colorectal, breast, lung cancers, melanoma and precancerous conditions as actinic keratosis. Pierre Fabre‘s expertise in dermatology, combined with its knowledge in the field of oncology, puts the company in a unique position to fight against skin cancers from multiple angles.
In 2019, Pierre Fabre generated 2.4 billion euros in revenues, of which two-thirds originated from its international business. Pierre Fabre, which has always been headquartered in the South-West of France, employs approximately 10,500 people worldwide, owns subsidiaries and offices in 45 countries and enjoys distribution agreements in over 130 countries. Pierre Fabre is 86%-owned by the Pierre Fabre Foundation, a government-recognised public-interest foundation since 1999, and secondarily by its own employees through an international employee stock ownership plan.
Learn more at www.pierre-fabre.com.
Roche was founded on October 1st, 1896. The founder, Fritz Hoffmann-La Roche, was among the first to recognize that the industrial manufacture of standardized medicines would be a major advance in the fight against disease.
From the very beginning, Roche’s visionary founder focused his company on innovation and on establishing an international presence. This multinational presence reinforces our ability to offer our healthcare solutions and to anticipate needs in all regions of the world. Today, Roche employs more than 85,000 people and sells its products in more than 150 countries.
Today Roche ranks among the world’s leading healthcare companies and has two strong core businesses: diagnostics and pharmaceuticals.
Read more about our company in our image brochure "Doing now what patients need next".
For more information, please visit www.roche.com.
Sponsors & Exhibitors:
We are a pioneering, clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection, and autoimmune disease.
Our initial therapeutic focus is in oncology, where pivotal clinical trials are currently underway in metastatic uveal melanoma, a rare form of eye cancer.
We also have a robust pipeline of programs spanning a broad range of cancer indications, as well as infectious and autoimmune diseases.
For more information, please visit www.Immunocore.com
Replimune is pioneering a new class of oncolytic immunotherapies (OI) designed to ignite a powerful patient-specific immune response to treat cancer and vaccinate against future relapse. The company’s Immulytic™ platform is intended to achieve the holy grail of personalized anti-cancer treatments — combining multiple mechanisms of action to deliver therapies with the ability to not only directly kill tumors and generate systemic anti-cancer immune responses, but to also create a practical, in situ approach to achieving personalized systemic anti-cancer vaccination. The approach is expected to be highly synergistic with immune checkpoint blockade and other methods of treatment across a broad range of cancers. With deep experience across drug development and commercialization the Replimune team is now focused on delivering therapies to patients that are intended to be significant improvements compared to what was previously possible, and which will broaden the use of OI well beyond immune responsive cancers to the full range of solid tumor types. Since September 2015, Replimune has built a portfolio of product candidates with three programs currently in the clinic. Its lead program, RP1, is in two registration directed clinical trials – in cutaneous squamous cell carcinoma and anti-PD1 failed melanoma – and is also being tested in other tumor types, including anti-PD1 failed non-small cell lung cancer.